vs

Side-by-side financial comparison of Invesco (IVZ) and Xylem Inc. (XYL). Click either name above to swap in a different company.

Xylem Inc. is the larger business by last-quarter revenue ($2.1B vs $1.7B, roughly 1.3× Invesco). Xylem Inc. runs the higher net margin — 8.9% vs -58.9%, a 67.8% gap on every dollar of revenue. On growth, Invesco posted the faster year-over-year revenue change (6.2% vs 2.7%). Over the past eight quarters, Invesco's revenue compounded faster (7.1% CAGR vs -1.0%).

Invesco Ltd. is an American independent investment management company headquartered in Atlanta, Georgia, with branch offices in 20 countries. Its common stock is a constituent of the S&P 500 and trades on the New York Stock Exchange. Invesco operates under the Invesco, Invesco Perpetual, and Powershares brand names.

Xylem is one of the two types of transport tissue in vascular plants, the other being phloem; both of these are part of the vascular bundle. The basic function of the xylem is to transport water upward from the roots to parts of the plants such as stems and leaves, but it also transports nutrients. The word xylem is derived from the Ancient Greek word ξύλον (xúlon), meaning "wood"; the best-known xylem tissue is wood, though it is found throughout a plant.

IVZ vs XYL — Head-to-Head

Bigger by revenue
XYL
XYL
1.3× larger
XYL
$2.1B
$1.7B
IVZ
Growing faster (revenue YoY)
IVZ
IVZ
+3.5% gap
IVZ
6.2%
2.7%
XYL
Higher net margin
XYL
XYL
67.8% more per $
XYL
8.9%
-58.9%
IVZ
Faster 2-yr revenue CAGR
IVZ
IVZ
Annualised
IVZ
7.1%
-1.0%
XYL

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
IVZ
IVZ
XYL
XYL
Revenue
$1.7B
$2.1B
Net Profit
$-995.9M
$189.0M
Gross Margin
37.8%
Operating Margin
-86.2%
11.5%
Net Margin
-58.9%
8.9%
Revenue YoY
6.2%
2.7%
Net Profit YoY
-575.8%
100.0%
EPS (diluted)
$-2.61
$0.79

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IVZ
IVZ
XYL
XYL
Q1 26
$2.1B
Q4 25
$1.7B
$2.4B
Q3 25
$1.6B
$2.3B
Q2 25
$1.5B
$2.3B
Q1 25
$1.5B
$2.1B
Q4 24
$1.6B
$2.3B
Q3 24
$1.5B
$2.1B
Q2 24
$1.5B
$2.2B
Net Profit
IVZ
IVZ
XYL
XYL
Q1 26
$189.0M
Q4 25
$-995.9M
$335.0M
Q3 25
$356.4M
$227.0M
Q2 25
$197.4M
$226.0M
Q1 25
$171.1M
$169.0M
Q4 24
$209.3M
$326.0M
Q3 24
$55.0M
$217.0M
Q2 24
$132.2M
$194.0M
Gross Margin
IVZ
IVZ
XYL
XYL
Q1 26
37.8%
Q4 25
38.9%
Q3 25
38.9%
Q2 25
38.8%
Q1 25
37.1%
Q4 24
38.0%
Q3 24
37.3%
Q2 24
37.8%
Operating Margin
IVZ
IVZ
XYL
XYL
Q1 26
11.5%
Q4 25
-86.2%
14.7%
Q3 25
16.5%
14.7%
Q2 25
14.1%
13.3%
Q1 25
18.1%
11.2%
Q4 24
19.6%
11.8%
Q3 24
6.6%
13.3%
Q2 24
13.9%
11.7%
Net Margin
IVZ
IVZ
XYL
XYL
Q1 26
8.9%
Q4 25
-58.9%
14.0%
Q3 25
21.7%
10.0%
Q2 25
13.0%
9.8%
Q1 25
11.2%
8.2%
Q4 24
13.1%
14.5%
Q3 24
3.6%
10.3%
Q2 24
8.9%
8.9%
EPS (diluted)
IVZ
IVZ
XYL
XYL
Q1 26
$0.79
Q4 25
$-2.61
$1.37
Q3 25
$0.66
$0.93
Q2 25
$-0.03
$0.93
Q1 25
$0.38
$0.69
Q4 24
$0.46
$1.33
Q3 24
$0.12
$0.89
Q2 24
$0.29
$0.80

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IVZ
IVZ
XYL
XYL
Cash + ST InvestmentsLiquidity on hand
$1.0B
$808.0M
Total DebtLower is stronger
$1.8B
$1.9B
Stockholders' EquityBook value
$12.2B
$11.0B
Total Assets
$27.1B
$17.0B
Debt / EquityLower = less leverage
0.15×
0.18×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IVZ
IVZ
XYL
XYL
Q1 26
$808.0M
Q4 25
$1.0B
$1.5B
Q3 25
$973.1M
$1.2B
Q2 25
$922.7M
$1.2B
Q1 25
$821.7M
$1.1B
Q4 24
$986.5M
$1.1B
Q3 24
$1.0B
$989.0M
Q2 24
$878.5M
$815.0M
Total Debt
IVZ
IVZ
XYL
XYL
Q1 26
$1.9B
Q4 25
$1.8B
$2.0B
Q3 25
$1.6B
$2.0B
Q2 25
$1.9B
$2.0B
Q1 25
$964.8M
$2.0B
Q4 24
$890.6M
$2.0B
Q3 24
$890.3M
Q2 24
$890.1M
Stockholders' Equity
IVZ
IVZ
XYL
XYL
Q1 26
$11.0B
Q4 25
$12.2B
$11.5B
Q3 25
$14.0B
$11.2B
Q2 25
$13.9B
$11.1B
Q1 25
$14.7B
$10.8B
Q4 24
$14.6B
$10.6B
Q3 24
$14.8B
$10.6B
Q2 24
$14.6B
$10.3B
Total Assets
IVZ
IVZ
XYL
XYL
Q1 26
$17.0B
Q4 25
$27.1B
$17.6B
Q3 25
$28.4B
$17.3B
Q2 25
$28.5B
$17.2B
Q1 25
$28.1B
$16.6B
Q4 24
$27.0B
$16.5B
Q3 24
$27.5B
$16.0B
Q2 24
$27.2B
$15.8B
Debt / Equity
IVZ
IVZ
XYL
XYL
Q1 26
0.18×
Q4 25
0.15×
0.17×
Q3 25
0.12×
0.18×
Q2 25
0.14×
0.18×
Q1 25
0.07×
0.19×
Q4 24
0.06×
0.19×
Q3 24
0.06×
Q2 24
0.06×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IVZ
IVZ
XYL
XYL
Operating Cash FlowLast quarter
$455.8M
Free Cash FlowOCF − Capex
$432.2M
FCF MarginFCF / Revenue
25.5%
Capex IntensityCapex / Revenue
1.4%
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.4B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IVZ
IVZ
XYL
XYL
Q1 26
Q4 25
$455.8M
$543.0M
Q3 25
$606.2M
$360.0M
Q2 25
$547.9M
$305.0M
Q1 25
$-84.6M
$33.0M
Q4 24
$316.9M
$575.0M
Q3 24
$438.4M
$311.0M
Q2 24
$489.1M
$288.0M
Free Cash Flow
IVZ
IVZ
XYL
XYL
Q1 26
Q4 25
$432.2M
$460.0M
Q3 25
$586.4M
$281.0M
Q2 25
$530.4M
$207.0M
Q1 25
$-108.0M
$-38.0M
Q4 24
$309.9M
$475.0M
Q3 24
$410.0M
$237.0M
Q2 24
$462.4M
$215.0M
FCF Margin
IVZ
IVZ
XYL
XYL
Q1 26
Q4 25
25.5%
19.2%
Q3 25
35.7%
12.4%
Q2 25
35.0%
9.0%
Q1 25
-7.1%
-1.8%
Q4 24
19.5%
21.1%
Q3 24
27.1%
11.3%
Q2 24
31.2%
9.9%
Capex Intensity
IVZ
IVZ
XYL
XYL
Q1 26
4.2%
Q4 25
1.4%
3.5%
Q3 25
1.2%
3.5%
Q2 25
1.2%
4.3%
Q1 25
1.5%
3.4%
Q4 24
0.4%
4.4%
Q3 24
1.9%
3.5%
Q2 24
1.8%
3.4%
Cash Conversion
IVZ
IVZ
XYL
XYL
Q1 26
Q4 25
1.62×
Q3 25
1.70×
1.59×
Q2 25
2.78×
1.35×
Q1 25
-0.49×
0.20×
Q4 24
1.51×
1.76×
Q3 24
7.97×
1.43×
Q2 24
3.70×
1.48×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IVZ
IVZ

Investment Advice$1.2B73%
Distribution And Shareholder Service$382.7M23%
Financial Service Other$51.0M3%
Investment Performance$28.9M2%

XYL
XYL

Revenue from products$1.8B83%
Revenue from services$368.0M17%

Related Comparisons